Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Is there a potential of circulating miRNAs as biomarkers in rheumatic diseases

K. Prajzlerová, L. Šenolt, M. Filková

. 2023 ; 10 (4) : 1263-1278. [pub] 20220907

Status neindexováno Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc23015819

MicroRNAs (miRNAs) are small non-coding single-stranded RNAs of about 22 nucleotides in length that act as post-transcriptional regulators of gene expression. Depending on the complementarity between miRNA and target mRNA, cleavage, destabilization, or translational suppression of mRNA occurs within the RISC (RNA-induced silencing complex). As gene expression regulators, miRNAs are involved in a variety of biological functions. Dysregulation of miRNAs and their target genes contribute to the pathophysiology of many diseases, including autoimmune and inflammatory disorders. MiRNAs are also present extracellularly in their stable form in body fluids. Their incorporation into membrane vesicles or protein complexes with Ago2, HDL, or nucleophosmin 1 protects them against RNases. Cell-free miRNAs can be delivered to another cell in vitro and maintain their functional potential. Therefore, miRNAs can be considered mediators of intercellular communication. The remarkable stability of cell-free miRNAs and their accessibility in body fluid makes them potential diagnostic or prognostic biomarkers and potential therapeutic targets. Here we provide an overview of the potential role of circulating miRNAs as biomarkers of disease activity, therapeutic response, or diagnosis in rheumatic diseases. Many circulating miRNAs reflect their involvement in the pathogenesis, while for plenty, their pathogenetic mechanisms remain to be explored. Several miRNAs described as biomarkers were also shown to be of therapeutic potential, and some miRNAs are already tested in clinical trials.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015819
003      
CZ-PrNML
005      
20231020093651.0
007      
ta
008      
231010s2023 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.gendis.2022.08.011 $2 doi
035    __
$a (PubMed)37397550
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Prajzlerová, Klára $u Institute of Rheumatology, Prague 12800, Czech Republic
245    10
$a Is there a potential of circulating miRNAs as biomarkers in rheumatic diseases / $c K. Prajzlerová, L. Šenolt, M. Filková
520    9_
$a MicroRNAs (miRNAs) are small non-coding single-stranded RNAs of about 22 nucleotides in length that act as post-transcriptional regulators of gene expression. Depending on the complementarity between miRNA and target mRNA, cleavage, destabilization, or translational suppression of mRNA occurs within the RISC (RNA-induced silencing complex). As gene expression regulators, miRNAs are involved in a variety of biological functions. Dysregulation of miRNAs and their target genes contribute to the pathophysiology of many diseases, including autoimmune and inflammatory disorders. MiRNAs are also present extracellularly in their stable form in body fluids. Their incorporation into membrane vesicles or protein complexes with Ago2, HDL, or nucleophosmin 1 protects them against RNases. Cell-free miRNAs can be delivered to another cell in vitro and maintain their functional potential. Therefore, miRNAs can be considered mediators of intercellular communication. The remarkable stability of cell-free miRNAs and their accessibility in body fluid makes them potential diagnostic or prognostic biomarkers and potential therapeutic targets. Here we provide an overview of the potential role of circulating miRNAs as biomarkers of disease activity, therapeutic response, or diagnosis in rheumatic diseases. Many circulating miRNAs reflect their involvement in the pathogenesis, while for plenty, their pathogenetic mechanisms remain to be explored. Several miRNAs described as biomarkers were also shown to be of therapeutic potential, and some miRNAs are already tested in clinical trials.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Šenolt, Ladislav $u Institute of Rheumatology, Prague 12800, Czech Republic $u Department of Rheumatology, First Faculty of Medicine, Charles University, Prague 12800, Czech Republic
700    1_
$a Filková, Mária $u Institute of Rheumatology, Prague 12800, Czech Republic $u Department of Rheumatology, First Faculty of Medicine, Charles University, Prague 12800, Czech Republic
773    0_
$w MED00213968 $t Genes & diseases $x 2352-3042 $g Roč. 10, č. 4 (2023), s. 1263-1278
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37397550 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20231020093644 $b ABA008
999    __
$a ok $b bmc $g 1997282 $s 1202181
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 10 $c 4 $d 1263-1278 $e 20220907 $i 2352-3042 $m Genes & diseases $n Genes Dis $x MED00213968
LZP    __
$a Pubmed-20231010

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...